Among these, compounds such as the tyrosine kinase inhibitor Tandutinib [23], the cell cycle inhibitor Palbociclib [24, 25], the anti-angiogenic agent Brivanib [26, 27], the anti-apoptotic B-cell lymphoma 2 (Bcl-2) inhibitor Navitoclax [28, 29], the CDK inhibitor Purvalanol A [30] and the histone deacetylase inhibitor Vorinostat [31] were validated as effective treatments for cancer, with their corresponding scores indicating their potential efficacy. Here, BCL2 is linked to cancer.